Bulevirtide Raised the Bar: Mirum's Brelovitug Phase 3 Win Faces a Market That Expects More

Mirum Pharmaceuticals reported Monday that brelovitug met its combined primary endpoint in the Phase 3 portion of the AZURE-1 study in chronic hepatitis delta virus, delivering virologic response and ALT normalization in more than half of patients on the weekly regimen at 24 weeks. By most standards, that is a clean pivotal win. The complication is the calendar. Gilead's Hepcludex already holds the first and only US approval for HDV, granted on an accelerated basis in May, and a third candidate from Vir Biotechnology is deep into its own registrational program. Mirum's shares dipped on the news rather than rallying, which tells you exactly how investors weighed a strong data readout against an increasingly crowded race.

What AZURE-1 showed

The Phase 3 portion enrolled 153 treatment-naive patients, randomized 2:2:1 to brelovitug 300 mg once weekly by subcutaneous self-administration, brelovitug 900 mg once every four weeks, or delayed treatment starting at Week 24. At Week 24, the combined primary endpoint, a virologic response of at least a 2 log10 reduction in HDV RNA from baseline or undetectable HDV RNA together with ALT normalization, was achieved by 56% of patients on the weekly regimen and 45% on the every-four-weeks regimen, versus 0% in the delayed treatment arm, with p<0.0001 for both comparisons, according to Mirum's release.

The components matter as much as the composite. Virologic response reached 86% in the weekly arm and 85% in the monthly arm, and ALT normalization landed at 63% and 54% respectively. Deep suppression showed up too: HDV RNA fell below the lower limit of quantification in 25% and 26% of patients, and the HDV RNA target was not detected in 17% in both arms. That last tier of depth is where a monoclonal antibody aimed at surface antigen distinguishes itself, because functional outcomes in HDV track with how far viral markers are pushed down, not merely whether they move.

The longer the treatment, the deeper the suppression

The most interesting signal may sit in the extension data from the Phase 2b portion, where the first 53 patients enrolled continued in an open-label extension through 48 weeks. Primary endpoint achievement rose from 45% to 55% in the 300 mg weekly arm and from 35% to 55% in the 900 mg every-four-weeks arm, and HDV RNA below the lower limit of quantification reached 80% in the weekly arm at Week 48. The monthly dose caught up on the composite endpoint, which is the kind of convergence that matters commercially: if 900 mg every four weeks closes the gap, brelovitug offers a genuine dosing wedge against a daily injection.

Safety through Week 24 was described as well tolerated with no new safety signals, though injection site reactions ran 10.2% in the weekly arm and 18.5% in the monthly arm, and one participant in the weekly arm experienced a Grade 4 acute myocardial infarction. A single serious cardiac event in a 153-patient study carries limited statistical weight, but it will be parsed closely once a bigger confirmatory dataset exists.

Three shots on goal, one approval already banked

The strategic picture is the hard part. Bulevirtide, an entry inhibitor dosed once daily by subcutaneous injection, won accelerated approval in May based on HDV RNA reductions and ALT normalization at Week 48 in the Phase 3 MYR301 study, with the FDA noting that improvement in disease-related clinical outcomes is not yet established and continued approval is contingent on confirmatory verification, per Gilead's announcement and the FDA's approval statement. Gilead pegs US prevalence at roughly 40,000 to 80,000 people, about 2% to 4% of those with chronic HBV, and its label carries a boxed warning for severe acute exacerbation of hepatitis D and B after discontinuation.

Mirum's candidate works differently. Brelovitug is a fully human IgG1 monoclonal antibody that binds hepatitis B surface antigen on both HDV and HBV, designed to neutralize and remove hepatitis B and D virions and deplete HBsAg-containing subviral particles. Mirum controls worldwide rights after picking up the asset through its acquisition of Bluejay Therapeutics, as described in the filing. Behind both of them, Vir Biotechnology advanced its tobevibart plus elebsiran combination from the Phase 2 SOLSTICE study into a Phase 3 registrational program, with complete Week 96 SOLSTICE data slated for presentation at EASL 2026, per Vir's announcement and its EASL notice.

The unmet need is real enough to support all three: Mirum cites roughly 230,000 people affected across the United States and Europe and estimates that more than half of individuals with HDV die of liver-related causes within 10 years of diagnosis.

The math Mirum now has to win

The regulatory path is orderly, with AZURE-4 topline expected in the fourth quarter of 2026, a BLA submission planned for the first half of 2027, and a potential US launch in the fourth quarter of 2027, under a Breakthrough Therapy designation. But the market reaction to a 56% response rate against a 0% control arm says something uncomfortable: the first-mover has already reset expectations. Mirum will be selling a second entrant into a small, specialist-treated population, and its differentiation has to carry the load. Weekly or monthly dosing versus a daily injection is a real convenience argument, and deep HBsAg depletion is a mechanistic argument, yet neither is proven to change hard outcomes in a disease where accelerated approval already exists on surrogate markers. Meanwhile Vir's combination program is still in flight, meaning the competitive window between brelovitug's possible launch and the next readout is narrow. If confirmatory data across the field converge on similar virologic and ALT benefits, the tiebreaker becomes dosing, tolerability, and pricing power in a market of tens of thousands of patients, and those are contests where an incumbent with an approved label and an established prescriber base rarely loses ground easily.